Silver: 12-month observation period runs smoothly Q1 sales show sustained growth in the business Q1 sales form a strong basis for growth in Q2 aap Implantate AG ("aap" or "Company") started the first quarter of 2025 with stable business development. Sales were on a par with the previous year. The EMEA region remained the strongest market region  [ … ]

On April 10, 2025, aap Implantate AG ("aap" or "Company") was informed by BaFin that it had issued a notice regarding the order to initiate an audit of the published consolidated financial statements and the associated Group management report for the 2023 financial year. The company is in close contact with BaFin in order to clarify the past facts [ … ]

aap Implantate AG ("aap" or "Company") has reached another important milestone in the transition from MDD (Medical Device Directive 93/42/EEC) to MDR (Medical Device Regulation EU 2017/745) and received the MDR certificate for its quality system following the successful audit with its Notified Body in September 2024.  The first medical devices Clas [ … ]

aap Implantate AG ("aap" or "Company") informs that with the end of a stable fourth quarter a preliminary sales growth of 6.3% compared to the previous year could be achieved. Growth was achieved in all regions except the USA. The investment in further aap systems to equip customers characterized the product mix, so that the company sees a good bas [ … ]